1Williams R. Global challenges in liver disease [ J ]. Hepatology, 2006, 44 ( 3 ) : 521 - 526.
2Rustgi VK, Davis GL, Herrine SK. Future trends in hepatology: challenges and opportunities [ J ]. Hepatology, 2008,48 (2) : 655 - 661.
3Ludwig J, Niggiano TR, McGill DB. et al. Nonalcoholic steatohepalitis: Mayo Clinic experiences with a hitherto unnamed disease[ J ]. Mayo Clin Proc, 1980, 55 ( 7 ) : 434 - 438.
4Cassiman D, Jaeken J. NASH may be trash[J]. Gut, 2008, 57(2) : 141 - 144.
5Brunt EM. What's in a NAme[J]. Hepatology, 2009, 50(3):663 - 667.
6Cortez - Pinto H, de Moura MC, Day CP. Non - alcoholic steatohepatitis: from cell biology to clinical practice [ J ]. J Hepatol, 2006, 44( 1): 197 -208.
7Fabbrini E, Sullivan S. Hlein S. Obesity and Nonalcoholic Fatty Liver Disease: Biochemical, Metabolic and clinical Implications [ J ]. Hepatology, 2010, 51 (2):679-689.
9Ratziu V, Poynard T. Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious [ J 3. Hepatology, 2006, 44 (4) : 802 - 805.
10Bugianesi E, McCullough A J, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease [ J ]. Hepatology, 2005, 42(5 ) : 987 - 1000.
二级参考文献79
1Farrell GC, Chitturi S, Lau GK, et al. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol, 2007. 22: 775-777.
2Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology, 2005,42:44-52.
3Ratziu V, Poynard T. Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious. Hepatology, 2006 , 44 : 802- 805.
4Poynard T, Lebray P, Varaud A, et al. Overestimation of "pure" non alcoholic fatty liver disease (NAFLD) as a cause of liver fibrosis (AF) using alcohol consumption estimated by self declaration (SD). J Hepatol, 2009,50:370.
5Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol, 2008,49 :608- 612.
6Beraza N, Trautwein C. The gut-brain-liver axis: a new option to treat obesity and diabetes? Hepatology, 2008,48 : 1011-1013.
7Vanni E, Bugianesi E. The gut-liver axis in nonalcoholic fatty liver disease: Another pathway to insulin resistance? Hepatology, 2009,49 : 1790-1792.
8Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology, 2009,49: 1877-1887.
9Berk PD. Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome. Hepatology, 2008,48 : 1362-1376.
10Milner KL, van der Poorten D, Xu A, et al. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology, 2009,49:1926-1934.
10MA LY, LIU RH, XU XD, et al. The pharmacokinetics of C-glycosyl flavones of Hawthorn leaf flavonoids in rat after single dose oral admin- istration [J] . Phytomedicine, 2010, 17 (8-9): 640-645.
